Bridgeway Capital Management’s Atea Pharmaceuticals AVIR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $515K | Hold |
143,100
| – | – | 0.01% | 774 |
|
|
2025
Q1 | $428K | Buy |
143,100
+109,800
| +330% | +$328K | 0.01% | 772 |
|
|
2024
Q4 | $112K | Buy |
+33,300
| New | +$112K | ﹤0.01% | 1099 |
|
|
2023
Q4 | – | Sell |
-379,912
| Closed | -$1.14M | – | 1364 |
|
|
2023
Q3 | $1.14M | Hold |
379,912
| – | – | 0.03% | 673 |
|
|
2023
Q2 | $1.42M | Hold |
379,912
| – | – | 0.03% | 646 |
|
|
2023
Q1 | $1.27M | Sell |
379,912
-8,000
| -2% | -$26.8K | 0.03% | 672 |
|
|
2022
Q4 | $1.87M | Buy |
387,912
+32,300
| +9% | +$155K | 0.05% | 568 |
|
|
2022
Q3 | $2.02M | Buy |
355,612
+8,000
| +2% | +$45.5K | 0.05% | 520 |
|
|
2022
Q2 | $2.47M | Buy |
347,612
+320,912
| +1,202% | +$2.28M | 0.06% | 475 |
|
|
2022
Q1 | $193K | Buy |
+26,700
| New | +$193K | ﹤0.01% | 1175 |
|